Suzhou Ribo Life Science and Ribocure Pharmaceuticals have announced the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA-based therapeutic for the treatment of Coronary Artery Disease (CAD). Lately, Ribo has been advancing multiple siRNA candidates in parallel across atrial fibrillation and venous thromboembolism, and has established an anticoagulation/antithrombotic pipeline. This new submission for CAD represents an important milestone in Ribo's program to advance innovative oligonucleotide-based therapies aimed at systematically addressing the root cause of thromboembolic diseases.

Dr. Anders Gabrielsen, Chief Medical Officer (CMO), Ribo, said, "We are very pleased to advance our anti-thrombotic siRNA programs into the next stage of clinical development in Europe. This milestone reflects our commitment to unlocking the full potential of RNA-based therapies to provide anticoagulant options with improved benefit-risk profile for patients not being adequately treated today."

CAD remains a leading cause of morbidity and mortality globally, driven by atherosclerotic plaque formation and associated thrombotic complications such as myocardial infarction and other ischemic events. Despite the widespread use of Standard of Care (SoC) therapies, including antiplatelet and anticoagulant therapies, a substantial residual risk of thrombotic events remains in patients with stable CAD, even when treated with optimised treatment. Current therapies are further limited by an increased risk of bleeding, restricting their intensity and long-term use in many patients.

Consequently, there is a significant unmet medical need for novel antithrombotic approaches that can provide effective and sustained protection against thrombosis while maintaining a favorable safety profile, particularly with respect to bleeding risk.